According to the MarketsandMarkets latest report “Cellular Health Screening/ Health Testing Market by Type (Single (Telomere, Oxidative Stress, Inflammation, Heavy Metal), Multitest), Sample (Blood, Saliva, Serum, Urine), Collection Site (Home, Office, Hospital, Diagnostic Labs), and Region - Global Forecast to 2022”
The global Cellular Health Testing Market is estimated to reach USD 3.42 billion by 2022 from USD 2.12 billion in 2017, at a CAGR of 10.0% during the forecast period.
Factors such as the increasing adoption of telomere performance programs for leading a healthy life; growing importance of healthy life expectancy (HALE); rising government focus towards preventive healthcare; rising geriatric population and resultant growth in the need for cellular health screening; increasing research activities; growing adoption of the direct-to-consumer approach; and the increasing burden of chronic diseases are expected to drive the growth of this market.
Download a FREE Pdf Brochure @:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=227041930
On the other hand, problems associated with the transport of samples and differences in the cost of test kits offered by different companies are expected to restrain the growth of this market during the forecast period.
This report segments the global market into type, sample type, sample collection site, and region. On the basis of type, the global market is segmented single test panels and multi-test panels. The multi-test panels segment is expected to grow at the highest CAGR during the forecast period. The preference for multi-test panels is increasing in the market as they provide results for multiple biomarkers in a single exam.
Read More
The global market is highly competitive with the presence of several small and big players. Prominent players in the cellular heath screening market include Genova Diagnostics (US), Telomere Diagnostics (US), Life Length (Spain), Quest Diagnostics (US), Repeat Diagnostics (Canada), SpectraCell Laboratories (US), Zimetry LLC (US), Cell Science Systems (US), Titanovo, Inc. (US), Segterra, Inc. (US), LabCorp Holdings (US), BioReference Laboratories (US), Immundiagnostik AG (Germany), and Cleveland HeartLab, Inc. (US).
The global Cellular Health Testing Market is estimated to reach USD 3.42 billion by 2022 from USD 2.12 billion in 2017, at a CAGR of 10.0% during the forecast period.
Factors such as the increasing adoption of telomere performance programs for leading a healthy life; growing importance of healthy life expectancy (HALE); rising government focus towards preventive healthcare; rising geriatric population and resultant growth in the need for cellular health screening; increasing research activities; growing adoption of the direct-to-consumer approach; and the increasing burden of chronic diseases are expected to drive the growth of this market.
Download a FREE Pdf Brochure @:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=227041930
On the other hand, problems associated with the transport of samples and differences in the cost of test kits offered by different companies are expected to restrain the growth of this market during the forecast period.
This report segments the global market into type, sample type, sample collection site, and region. On the basis of type, the global market is segmented single test panels and multi-test panels. The multi-test panels segment is expected to grow at the highest CAGR during the forecast period. The preference for multi-test panels is increasing in the market as they provide results for multiple biomarkers in a single exam.
Read More
The global market is highly competitive with the presence of several small and big players. Prominent players in the cellular heath screening market include Genova Diagnostics (US), Telomere Diagnostics (US), Life Length (Spain), Quest Diagnostics (US), Repeat Diagnostics (Canada), SpectraCell Laboratories (US), Zimetry LLC (US), Cell Science Systems (US), Titanovo, Inc. (US), Segterra, Inc. (US), LabCorp Holdings (US), BioReference Laboratories (US), Immundiagnostik AG (Germany), and Cleveland HeartLab, Inc. (US).
Comments
Post a Comment